22 (1) The drug benefit price for a drug product when it becomes a listed drug product shall be the amount agreed to by the executive officer and the manufacturer, subject to any conditions that may be prescribed.  2006, c. 14, s. 28. Executive officer’s agreement (2) In deciding whether to agree to an amount under subsection (1), the executive officer may consider any matter the executive officer considers advisable in the public interest, including, without limiting the generality of the foregoing, the drug benefit price of other drug products or the price charged to operators of pharmacies for the drug product or other drug products.  2006, c. 14, s. 28. Request for change (3) A manufacturer may request, in writing, that the executive officer change a drug benefit price, but the executive officer is not obligated to act on the request.  2006, c. 14, s. 28. Criteria for requesting change (4) The executive officer may establish rules, criteria and procedures that must be followed by a manufacturer in submitting requests for changes in a drug benefit price, including providing for how often such requests may be made, and shall post those rules, criteria and procedures on the Ministry’s website and in any other format the executive officer considers advisable.  2006, c. 14, s. 28. Manufacturer must comply (5) A manufacturer that submits a request for a change in a drug benefit price shall comply with the posted rules, criteria and procedures.  2006, c. 14, s. 28. Where conflict (6) In the event of a conflict between what is posted on the Ministry’s website under subsection (4) and what is posted in another format, the Ministry’s website prevails.  2006, c. 14, s. 28. Changing drug benefit price (7) Subject to any conditions that may be prescribed, the executive officer may change the drug benefit price of a drug product in consultation with the manufacturer if a request has been made under subsection (3) and the executive officer considers it to be in the public interest to make the change, and such a change is effective on the date that it is indicated in the Formulary as taking effect.  2006, c. 14, s. 28. Documentation (8) In determining whether a change in the drug benefit price is in the public interest, the executive officer may require the manufacturer to supply any information, other than personal information, that the executive officer considers relevant, and the manufacturer shall comply with the request.  2006, c. 14, s. 28. Transitional (9) The drug benefit price of a drug product that was a listed drug product immediately before October 1, 2006 shall be its drug benefit price as it existed under this Act at that time, until it is changed as permitted under this Act and the regulations.  2006, c. 14, s. 28. Change, previously listed drugs (10) The executive officer may, in accordance with the prescribed conditions, change the drug benefit price of any drug product that was listed in the Formulary that existed immediately before October 1, 2006 and that was referred to in the regulations made under this Act or the Drug Interchangeability and Dispensing Fee Act.  2006, c. 14, s. 28. Section Amendments with date in force (d/m/y) 1996, c. 1, Sched. G, s. 17 - 27/05/1996 2006, c. 14, s. 28 - 01/10/2006